Home > Documents in Process > The evolving landscape of Alzheimer's disease therapy: From Aβ to tau. > print

001     283060
005     20251229124832.0
024 7 _ |a 10.1016/j.cell.2025.11.033
|2 doi
024 7 _ |a pmid:41448139
|2 pmid
024 7 _ |a 0092-8674
|2 ISSN
024 7 _ |a 1097-4172
|2 ISSN
037 _ _ |a DZNE-2025-01467
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Courade, Jean-Philippe
|b 0
245 _ _ |a The evolving landscape of Alzheimer's disease therapy: From Aβ to tau.
260 _ _ |a [Cambridge, Mass.]
|c 2025
|b Cell Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1767008744_31206
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a A marked evolution in Alzheimer's disease (AD) therapy research is ongoing. In this perspective, we highlight emerging outcomes of tau-targeting approaches with disease-modifying potential evidenced by PET-based slowing of tau accumulation and early signs of cognitive benefit. We outline how decades of iterative amyloid β (Aβ)-trial refinement leading to the recent successes of approved anti-Aβ therapies have set the stage for accelerated optimization of next-generation trials. We summarize key learnings from first-generation tau immunotherapies and how these paved the way for early achievements in tau trials, while many challenges remain. Finally, we discuss the back-translation of clinical outcomes into fundamental insights on human tau pathobiology, and we outline challenges and future directions for AD therapy development including combination therapy and targets beyond Aβ/tau. Together, this provides a framework for next-generation AD and tau-therapy development toward increasingly efficient disease-halting interventions.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a A(I)TN
|2 Other
650 _ 7 |a ASO
|2 Other
650 _ 7 |a AT(X)N
|2 Other
650 _ 7 |a ATN
|2 Other
650 _ 7 |a Abeta therapy
|2 Other
650 _ 7 |a Alzheimer's disease
|2 Other
650 _ 7 |a PET imaging
|2 Other
650 _ 7 |a amyloid
|2 Other
650 _ 7 |a anti-sense oligonucleotides
|2 Other
650 _ 7 |a clinical trial
|2 Other
650 _ 7 |a immunization
|2 Other
650 _ 7 |a inflammation
|2 Other
650 _ 7 |a neurodegeneration
|2 Other
650 _ 7 |a next-generation therapies
|2 Other
650 _ 7 |a tau
|2 Other
650 _ 7 |a tau therapy
|2 Other
650 _ 7 |a tauopathies
|2 Other
650 _ 7 |a therapy development
|2 Other
650 _ 7 |a trial
|2 Other
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 2 |a Alzheimer Disease: therapy
|2 MeSH
650 _ 2 |a Alzheimer Disease: metabolism
|2 MeSH
650 _ 2 |a Alzheimer Disease: drug therapy
|2 MeSH
650 _ 2 |a Alzheimer Disease: pathology
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
650 _ 2 |a tau Proteins: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Immunotherapy: methods
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Clinical Trials as Topic
|2 MeSH
700 1 _ |a Zetterberg, Henrik
|b 1
700 1 _ |a Höglinger, Günter U
|0 P:(DE-2719)2811373
|b 2
|u dzne
700 1 _ |a Dewachter, Ilse
|b 3
773 _ _ |a 10.1016/j.cell.2025.11.033
|g Vol. 188, no. 26, p. 7337 - 7354
|0 PERI:(DE-600)2001951-8
|n 26
|p 7337 - 7354
|t Cell
|v 188
|y 2025
|x 0092-8674
856 4 _ |u https://pub.dzne.de/record/283060/files/DZNE-2025-1467.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/283060/files/DZNE-2025-1467.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811373
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-01-01
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-01
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-01
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL : 2022
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-01
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-01
915 _ _ |a IF >= 60
|0 StatID:(DE-HGF)9960
|2 StatID
|b CELL : 2022
|d 2025-01-01
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21